121 related articles for article (PubMed ID: 35855585)
61. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.
Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R
JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048
[TBL] [Abstract][Full Text] [Related]
62. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
63. Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States.
Abara WE; Gee J; Marquez P; Woo J; Myers TR; DeSantis A; Baumblatt JAG; Woo EJ; Thompson D; Nair N; Su JR; Shimabukuro TT; Shay DK
JAMA Netw Open; 2023 Feb; 6(2):e2253845. PubMed ID: 36723942
[TBL] [Abstract][Full Text] [Related]
64. Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women.
Goldshtein I; Nevo D; Steinberg DM; Rotem RS; Gorfine M; Chodick G; Segal Y
JAMA; 2021 Aug; 326(8):728-735. PubMed ID: 34251417
[TBL] [Abstract][Full Text] [Related]
65. COVID-19 vaccination in people with multiple sclerosis, real-life experience.
Alroughani R; Al-Hashel J; Abokalawa F; AlMojel M; Farouk Ahmed S
Clin Neurol Neurosurg; 2022 Sep; 220():107374. PubMed ID: 35961255
[TBL] [Abstract][Full Text] [Related]
66. Adverse Events Following Immunization With mRNA and Viral Vector Vaccines in Individuals With Previous Severe Acute Respiratory Syndrome Coronavirus 2 Infection From the Canadian National Vaccine Safety Network.
Bettinger JA; Irvine MA; Shulha HP; Valiquette L; Muller MP; Vanderkooi OG; Kellner JD; Top KA; Sadarangani M; McGeer A; Isenor JE; Marty K; Soe P; De Serres G;
Clin Infect Dis; 2023 Mar; 76(6):1088-1102. PubMed ID: 36310514
[TBL] [Abstract][Full Text] [Related]
67. Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community.
Abukhalil AD; Shatat SS; Abushehadeh RR; Al-Shami N; Naseef HA; Rabba A
BMC Infect Dis; 2023 Jan; 23(1):5. PubMed ID: 36604613
[TBL] [Abstract][Full Text] [Related]
68. Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination.
Kim HW; Jenista ER; Wendell DC; Azevedo CF; Campbell MJ; Darty SN; Parker MA; Kim RJ
JAMA Cardiol; 2021 Oct; 6(10):1196-1201. PubMed ID: 34185046
[TBL] [Abstract][Full Text] [Related]
69. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Liu X; Shaw RH; Stuart ASV; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Dinesh T; England A; Faust SN; Ferreira DM; Finn A; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Lazarus R; Libri V; Long F; Mujadidi YF; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Singh N; Turner DPJ; Turner PJ; Walker LL; White R; Nguyen-Van-Tam JS; Snape MD;
Lancet; 2021 Sep; 398(10303):856-869. PubMed ID: 34370971
[TBL] [Abstract][Full Text] [Related]
70. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada.
Buchan SA; Seo CY; Johnson C; Alley S; Kwong JC; Nasreen S; Calzavara A; Lu D; Harris TM; Yu K; Wilson SE
JAMA Netw Open; 2022 Jun; 5(6):e2218505. PubMed ID: 35749115
[TBL] [Abstract][Full Text] [Related]
71. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.
Thomas SJ; Moreira ED; Kitchin N; Absalon J; Gurtman A; Lockhart S; Perez JL; Pérez Marc G; Polack FP; Zerbini C; Bailey R; Swanson KA; Xu X; Roychoudhury S; Koury K; Bouguermouh S; Kalina WV; Cooper D; Frenck RW; Hammitt LL; Türeci Ö; Nell H; Schaefer A; Ünal S; Yang Q; Liberator P; Tresnan DB; Mather S; Dormitzer PR; Şahin U; Gruber WC; Jansen KU;
N Engl J Med; 2021 Nov; 385(19):1761-1773. PubMed ID: 34525277
[TBL] [Abstract][Full Text] [Related]
72. Serological findings following the second and third SARS-CoV-2 vaccines in lung transplant recipients.
Bárczi E; Varga V; Nagy A; Eszes N; Jáky-Kováts Z; Müller V; Bohács A
Immun Inflamm Dis; 2022 Aug; 10(8):e646. PubMed ID: 35894705
[TBL] [Abstract][Full Text] [Related]
73. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
[TBL] [Abstract][Full Text] [Related]
74. Safety and effectiveness of vaccines against COVID-19 in children aged 5-11 years: a systematic review and meta-analysis.
Piechotta V; Siemens W; Thielemann I; Toews M; Koch J; Vygen-Bonnet S; Kothari K; Grummich K; Braun C; Kapp P; Labonté V; Wichmann O; Meerpohl JJ; Harder T
Lancet Child Adolesc Health; 2023 Jun; 7(6):379-391. PubMed ID: 37084750
[TBL] [Abstract][Full Text] [Related]
75. Vaccines and Bell's palsy: A narrative review.
Bertin B; Grenet G; Pizzoglio-Billaudaz V; Lepelley M; Atzenhoffer M; Vial T
Therapie; 2023; 78(3):279-292. PubMed ID: 36038397
[TBL] [Abstract][Full Text] [Related]
76. Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine.
Moreira ED; Kitchin N; Xu X; Dychter SS; Lockhart S; Gurtman A; Perez JL; Zerbini C; Dever ME; Jennings TW; Brandon DM; Cannon KD; Koren MJ; Denham DS; Berhe M; Fitz-Patrick D; Hammitt LL; Klein NP; Nell H; Keep G; Wang X; Koury K; Swanson KA; Cooper D; Lu C; Türeci Ö; Lagkadinou E; Tresnan DB; Dormitzer PR; Şahin U; Gruber WC; Jansen KU;
N Engl J Med; 2022 May; 386(20):1910-1921. PubMed ID: 35320659
[TBL] [Abstract][Full Text] [Related]
77. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O
JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256
[TBL] [Abstract][Full Text] [Related]
78. Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study.
Haas EJ; McLaughlin JM; Khan F; Angulo FJ; Anis E; Lipsitch M; Singer SR; Mircus G; Brooks N; Smaja M; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet Infect Dis; 2022 Mar; 22(3):357-366. PubMed ID: 34562375
[TBL] [Abstract][Full Text] [Related]
79. Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children.
Dionne A; Sperotto F; Chamberlain S; Baker AL; Powell AJ; Prakash A; Castellanos DA; Saleeb SF; de Ferranti SD; Newburger JW; Friedman KG
JAMA Cardiol; 2021 Dec; 6(12):1446-1450. PubMed ID: 34374740
[TBL] [Abstract][Full Text] [Related]
80. Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine.
Bookstein Peretz S; Regev N; Novick L; Nachshol M; Goffer E; Ben-David A; Asraf K; Doolman R; Levin EG; Regev Yochay G; Yinon Y
Ultrasound Obstet Gynecol; 2021 Sep; 58(3):450-456. PubMed ID: 34198360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
